Oseltamivir Phosphate with at Least a 10-year Shelf Life
Health and Human Services (all) · ASPR/ORM-SNS
No listed company matched (Materiality N/A)
Capture briefs (a one-page, shareable copy of this page) are part of Pro. The CSV here holds the notice, its timeline and past awards.
Where this opportunity stands
Every notice posted under solicitation 75A50325F80003 in this department, oldest first.
- Jan 31, 2025 · this noticeAward NoticeGENENTECH USA, INC · $397.0M
Next steps for this stage
Standard steps for the notice type; not advice about this buyer.
- Note the winner and the end of the period of performance for the recompete.
- Follow the agency to see the next notice for this work.
What the notice says
Delivery order 75A50325F80003 was awarded under the authority of a Limited Source Justification pursuant to FAR 8.405-6(a)(1)(i)(B), only one source is capable of providing the supplies required at the level or quality required because the supplies or services are unique or highly specialized for the supply of oseltamivir phosphate with at least a 10-year shelf life. The NAICS code for this procurement is 325412, Pharmaceutical and Preparation Manufacturing. Period of performance � from date of award for 24 months thereafter. The Administration for Strategic Preparedness and Response, Center f… (show all)
or the Strategic National Stockpile (SNS) awarded a firm fixed-price delivery order to Genentech USA, Inc., located at 1 DNA Way, South San Francisco, CA 94080-4918. This delivery order was awarded to replace expiring Tamiflu (oseltamivir phosphate) 30mg and 75mg capsules with long shelf-life oseltamivir phosphate 30mg and 75mg capsules with at least a 10-year shelf-life. Replacement ensures that the SNS maintains its stockpile of Influenza antivirals that have long-term stability and potency, and that remain deployable and available for an emergency without any additional procurement or government-funded drug stability studies. Oseltamivir phosphate is an antiviral medication primarily used to treat acute Influenza A and B in patients experiencing symptoms for less than 48 hours. Oseltamivir phosphate works by inhibiting a key enzyme necessary for viral replication, reducing the severity and duration of flu symptoms, facilitating faster recovery, and offering preventative benefits when exposure to the virus occurs.
Who won similar work
5 award notices on SAM.gov in the last 24 months. Matched by: Same office (ASPR/ORM-SNS), same product/service code (PSC) 6505 and NAICS 325412.
Single-winner award sizes (5): middle half $45.5M to $80.5M, median $46.2M; range $16.2M to $168.0M.
| Winner | Awards | Value | Last |
|---|---|---|---|
| CHARTWELL RX LLC | 1 | $168.0M | Jun 20, 2025 |
| Multiple Contract Awards - See Description Atlanta GA USA | 1 | $80.5M | Oct 2, 2026 |
| RAFA LABORATORIES LTD. | 1 | $46.2M | Oct 10, 2025 |
| GLAXOSMITHKLINE LLC | 1 | $45.5M | Oct 10, 2025 |
| HEYLTEX CORPORATION | 1 | $16.2M | Oct 10, 2025 |
Value counts new single-winner awards. "Shared" awards are multiple-award contracts that list every winner with the same total ceiling (same contract, or the same office, day and amount); that ceiling is not one company's win, so it is not added in. Contract modifications are not new awards and are not added in either. Revenue next to a ticker is the company's revenue over the latest 12 months in its SEC filings.
- Oct 2, 2026Multiple Contract Awards - See Description Atlanta GA USA$80.5MSNS Pharmaceutical Logistic Replenishment RequirementNo listed company matched (Materiality N/A)
- Oct 10, 2025GLAXOSMITHKLINE LLC$45.5MRelenza (Zanamivir) Rotadisk, 5MGNo listed company matched (Materiality N/A)
- Oct 10, 2025RAFA LABORATORIES LTD.$46.2MAtropine Auto-Injectors (0.5 mg, 1 mg, and 2 mg)No listed company matched (Materiality N/A)
- Oct 10, 2025HEYLTEX CORPORATION$16.2MPrussian Blue (Radiogardase), Insoluble Cap, 500 mgNo listed company matched (Materiality N/A)
- Jun 20, 2025CHARTWELL RX LLC$168.0MDoxycycline hyclate 100 mg oral tabletsNo listed company matched (Materiality N/A)
Competitive landscape
For the 5 most frequent past winners above. Lobbying is matched by the company's exact name or exact ticker; agencies are as named on the filings.
- 2 of these past winners lobbied Health & Human Services, Dept of (HHS) since 2024 (15 filings)
- 0 of their lobbyists list a past Health & Human Services, Dept of (HHS) job
- No corporate PAC money from them to the overseeing committees since 2024
- 0 foreign-agent (FARA) registrations
Policy around it
Bills the past winners named while lobbying this agency's issues, rules from the department, and executive orders that name the agency, last 12 months.
- 0 bills named on the past winners' lobbying filings
- 253 rules from the department in the last 12 months
- 0 executive orders naming the agency in the last 12 months
Market
For past winners matched exactly to a listed company. Insider trades are open-market buys and sells (Form 4) in the last 90 days, shown as facts; our own study found insiders do not reliably buy ahead of awards. A sale marked 10b5-1 was made under a trading plan set up in advance.
- 0 of the past winners are listed companies
- 0 insider buys and 0 insider sells at them in the last 90 days
Sources: SAM.gov notices and award notices; Senate LDA lobbying filings; FEC filings; FARA; Federal Register; congress.gov; SEC Form 4. Every row above links to its record.
Companies are matched to tickers by exact name, including the subsidiaries a company lists in its SEC filings. A company we could not match shows no market rows; that is a miss, not a finding.